PEARL: Postmenopausal Evaluation And Risk-Reduction With Lasofoxifene
PEARL: Postmenopausal Evaluation And Risk-Reduction With Lasofoxifene
The purpose of the study is to determine the safety and effectiveness of 2 doses of the investigational drug, lasofoxifene, compared to placebo (an inactive substance) in reducing new spinal fractures in women with osteoporosis.
Inclusion Criteria:
Postmenopausal at least 5 years; Screening bone mineral density more than or equal to 2.5 S.D.s below the mean for young adults at the lumbar spine or femoral neck.
Exclusion Criteria:
Metabolic bone disease other than osteoporosis; Taking approved medications for osteoporosis; Have had a recent osteoporotic fracture (within 1 year) and/or have a bone mineral density more than 4.5 S.D.s below the mean for young adults at the lumbar spine or femoral neck.
Charleroia, Pennsylvania 15022, United States
Capital Federal, Buenos Aires C1114AAH, Argentina
Capital Federal, Buenos Aires C1117ABH, Argentina
Capital Federal - Buenos Aires, C1012AAP, Argentina
Capital Federal, C1115AAJ, Argentina
Capital Federal, C1428AQK, Argentina
S2000dhl- Rosario - Santa Fe, Argentina
Paseo Colon, Provincia de San José, Costa Rica
Heliopolis, Cairo, Egypt
Hyderabad, Andhra Pradesh 500 033, India
Parel, Mumbai, 400 012, India
15-3-1 Maki Ohita-shi, Ohita-ken, Japan
Ohita, Ohita, Japan
2-7-8 Yoyogi Shibuya-ku, Tokyo, Japan
Shinjuku-ku, Tokyo, Japan
Cp 11800, Mexico Df, Mexico
Nowogrodzka 62A, Warszawa 02-002, Poland
Northwood, Middlesex, HA6 2RN, United Kingdom